TWI607006B - 細胞凋亡蛋白抑制劑之固體口服調配物及晶型 - Google Patents

細胞凋亡蛋白抑制劑之固體口服調配物及晶型 Download PDF

Info

Publication number
TWI607006B
TWI607006B TW099126987A TW99126987A TWI607006B TW I607006 B TWI607006 B TW I607006B TW 099126987 A TW099126987 A TW 099126987A TW 99126987 A TW99126987 A TW 99126987A TW I607006 B TWI607006 B TW I607006B
Authority
TW
Taiwan
Prior art keywords
compound
formulation
ray diffraction
powder
ethyl
Prior art date
Application number
TW099126987A
Other languages
English (en)
Chinese (zh)
Other versions
TW201118091A (en
Inventor
基汪 薩庫爾
楊東
馮麗麗
Original Assignee
諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI607006(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 諾華公司 filed Critical 諾華公司
Publication of TW201118091A publication Critical patent/TW201118091A/zh
Application granted granted Critical
Publication of TWI607006B publication Critical patent/TWI607006B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW099126987A 2009-08-12 2010-08-12 細胞凋亡蛋白抑制劑之固體口服調配物及晶型 TWI607006B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27405109P 2009-08-12 2009-08-12

Publications (2)

Publication Number Publication Date
TW201118091A TW201118091A (en) 2011-06-01
TWI607006B true TWI607006B (zh) 2017-12-01

Family

ID=42937834

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099126987A TWI607006B (zh) 2009-08-12 2010-08-12 細胞凋亡蛋白抑制劑之固體口服調配物及晶型

Country Status (24)

Country Link
US (4) US8623385B2 (enExample)
EP (1) EP2464644A1 (enExample)
JP (3) JP2013501751A (enExample)
KR (2) KR20180020315A (enExample)
CN (2) CN102471331B (enExample)
AR (1) AR077869A1 (enExample)
AU (4) AU2010283748A1 (enExample)
BR (1) BR112012003118A2 (enExample)
CA (1) CA2769616A1 (enExample)
CL (1) CL2012000349A1 (enExample)
CO (1) CO6612189A2 (enExample)
IL (1) IL217760A0 (enExample)
IN (1) IN2012DN00858A (enExample)
MA (1) MA33511B1 (enExample)
MX (2) MX351274B (enExample)
MY (1) MY160475A (enExample)
PE (2) PE20121132A1 (enExample)
PH (1) PH12014501890A1 (enExample)
RU (1) RU2671196C1 (enExample)
SG (1) SG177713A1 (enExample)
TN (1) TN2012000026A1 (enExample)
TW (1) TWI607006B (enExample)
WO (1) WO2011018474A1 (enExample)
ZA (1) ZA201200390B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017253560B2 (en) 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119060A1 (en) * 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
AU2003249920A1 (en) 2002-07-02 2004-01-23 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
AU2005231956B2 (en) 2004-04-07 2009-11-05 Novartis Ag Inhibitors of IAP
KR101278732B1 (ko) 2004-12-20 2013-07-09 제넨테크, 인크. Iap의 피롤리딘 억제제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors

Also Published As

Publication number Publication date
EP2464644A1 (en) 2012-06-20
PE20170777A1 (es) 2017-07-04
MA33511B1 (fr) 2012-08-01
US20170081319A1 (en) 2017-03-23
US8623385B2 (en) 2014-01-07
AU2014213533A1 (en) 2014-09-04
AU2016203145A1 (en) 2016-06-02
KR20180020315A (ko) 2018-02-27
US20140093570A1 (en) 2014-04-03
RU2012108931A (ru) 2013-09-27
KR20120048008A (ko) 2012-05-14
WO2011018474A8 (en) 2011-09-22
AR077869A1 (es) 2011-09-28
JP2016179976A (ja) 2016-10-13
IL217760A0 (en) 2012-03-29
CN105646471A (zh) 2016-06-08
AU2010283748A1 (en) 2012-02-09
TW201118091A (en) 2011-06-01
ZA201200390B (en) 2012-10-31
SG177713A1 (en) 2012-02-28
PH12014501890B1 (en) 2015-09-14
CO6612189A2 (es) 2013-02-01
US10093665B2 (en) 2018-10-09
MX2012001844A (es) 2012-02-29
US20120128742A1 (en) 2012-05-24
JP2018172403A (ja) 2018-11-08
RU2671196C1 (ru) 2018-10-30
US9540363B2 (en) 2017-01-10
AU2017254950A1 (en) 2017-11-23
CN102471331B (zh) 2016-01-13
IN2012DN00858A (enExample) 2015-07-10
WO2011018474A1 (en) 2011-02-17
AU2017254950B2 (en) 2018-09-20
PH12014501890A1 (en) 2015-09-14
CL2012000349A1 (es) 2012-09-07
JP2013501751A (ja) 2013-01-17
MX351274B (es) 2017-10-06
CN102471331A (zh) 2012-05-23
TN2012000026A1 (en) 2013-09-19
PE20121132A1 (es) 2012-09-04
CA2769616A1 (en) 2011-02-17
US20180370960A1 (en) 2018-12-27
BR112012003118A2 (pt) 2016-02-23
MY160475A (en) 2017-03-15

Similar Documents

Publication Publication Date Title
JP6756617B2 (ja) N−{4−[(6,7−ジメトキシキノリン−4−イル)オキシ]フェニル}−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法
TWI788702B (zh) {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途
JP7659097B2 (ja) N-{4-[(6,7-ジメトキシキノリン-4-イル)オキシ]フェニル}-n’-(4-フルオロフェニル)シクロプロパン-1,1-ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法
JP6969848B2 (ja) プリナブリン組成物
CN103842360B (zh) 用于药物制剂的具有特定粒度分布范围和比表面积范围的n-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物
CN113480542A (zh) 化合物的固体形式和制剂
CN108884080B (zh) 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
JP2015518891A (ja) 抗ウイルス化合物の固体形態
TW202444377A (zh) 包括ent1抑制劑之鹽、結晶形式及水合物與溶劑合物的硫酸氫複合物
TWI607006B (zh) 細胞凋亡蛋白抑制劑之固體口服調配物及晶型
BRPI0716243A2 (pt) sais de Éteres benzimidazolil piridÍlicos e formulaÇÕes dos mesmos
JP2018168153A (ja) 6−{2−[1−(6−メチル−3−ピリダジニル)−4−ピペリジニル]エトキシ}−3−エトキシ−1,2−ベンゾイソオキサゾールの無水結晶性遊離塩基形態
US20220017490A1 (en) Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
CN109963565B (zh) 一种药物组合物及其制备方法
RU2574405C2 (ru) Твердые пероральные составы и кристаллические формы ингибитора белка апоптоза
HK40020497B (en) Crystalline solid forms of salts, processes for making, and methods of use
NZ719970B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
NZ759132B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees